0000950170-24-004656.txt : 20240116 0000950170-24-004656.hdr.sgml : 20240116 20240116163545 ACCESSION NUMBER: 0000950170-24-004656 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240110 FILED AS OF DATE: 20240116 DATE AS OF CHANGE: 20240116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Neill Andrew R CENTRAL INDEX KEY: 0001827204 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39593 FILM NUMBER: 24535619 MAIL ADDRESS: STREET 1: 1018 W 11TH STREET, SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Shattuck Labs, Inc. CENTRAL INDEX KEY: 0001680367 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812575858 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 W. 5TH STREET CITY: AUSTIN STATE: TX ZIP: 78701 BUSINESS PHONE: 512-900-4690 MAIL ADDRESS: STREET 1: 500 W. 5TH STREET CITY: AUSTIN STATE: TX ZIP: 78701 4 1 ownership.xml 4 X0508 4 2024-01-10 0001680367 Shattuck Labs, Inc. STTK 0001827204 Neill Andrew R C/O SHATTUCK LABS, INC. 500 W. 5TH STREET, SUITE 1200 AUSTIN TX 78701 false true false false Chief Financial Officer true Common Stock 2024-01-10 4 A false 56500 0.00 A 200916 D Common Stock 2024-01-10 4 F false 2470 10.09 D 198446 D Common Stock 2024-01-10 4 S false 25000 10.00 D 173446 D Stock Option (Right to Buy) 10.09 2024-01-10 4 A false 113000 0.00 A 2034-01-10 Common Stock 113000 113000 D Consists of 56,500 restricted stock units, which will vest in four equal annual installments beginning on January 10, 2025, subject to the Reporting Person's continued service to the Issuer. This option represents a right to purchase a total of 113,000 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2025, with the remaining three quarters vesting in equal monthly installments through January 10, 2028, subject to the Reporting Person's continued service to the Issuer. /s/ Andrew R. Neill 2024-01-16